Stock Track | Moderna Soars 5% as U.S. Government Awards $590 Million Bird Flu Vaccine Contract

Stock Track

Jan 22, 2025

Moderna, Inc. (MRNA) shares surged 5.02% in intraday trading on Wednesday, January 22nd, fueled by news that the company secured a $590 million contract from the U.S. government to accelerate the development of a bird flu vaccine.

The substantial contract award from the U.S. government is a significant boost for Moderna's efforts to expand its vaccine portfolio beyond its successful COVID-19 vaccine. The funds will be used to speed up the research, development, and clinical testing of a vaccine candidate targeting the highly pathogenic avian influenza virus, commonly known as bird flu.

Moderna's share price rally reflects investor optimism about the company's potential to leverage its mRNA technology platform to address emerging infectious disease threats. The bird flu vaccine program underscores Moderna's commitment to advancing its pipeline and solidifying its position as a leading player in the global vaccine market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1189535129"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189535129\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1189535129?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-22 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189535129","market":"us","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5% as U.S. Government Awards $590 Million Bird Flu Vaccine Contract","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) shares surged 5.02% in intraday trading on Wednesday, January 22nd, fueled by news that the company secured a $590 million contract from the U.S. government to accelerate the development of a bird flu vaccine.</p>\n\n<p>The substantial contract award from the U.S. government is a significant boost for Moderna's efforts to expand its vaccine portfolio beyond its successful COVID-19 vaccine. The funds will be used to speed up the research, development, and clinical testing of a vaccine candidate targeting the highly pathogenic avian influenza virus, commonly known as bird flu.</p>\n\n<p>Moderna's share price rally reflects investor optimism about the company's potential to leverage its mRNA technology platform to address emerging infectious disease threats. The bird flu vaccine program underscores Moderna's commitment to advancing its pipeline and solidifying its position as a leading player in the global vaccine market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5% as U.S. Government Awards $590 Million Bird Flu Vaccine Contract</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5% as U.S. Government Awards $590 Million Bird Flu Vaccine Contract\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-22 22:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) shares surged 5.02% in intraday trading on Wednesday, January 22nd, fueled by news that the company secured a $590 million contract from the U.S. government to accelerate the development of a bird flu vaccine.</p>\n\n<p>The substantial contract award from the U.S. government is a significant boost for Moderna's efforts to expand its vaccine portfolio beyond its successful COVID-19 vaccine. The funds will be used to speed up the research, development, and clinical testing of a vaccine candidate targeting the highly pathogenic avian influenza virus, commonly known as bird flu.</p>\n\n<p>Moderna's share price rally reflects investor optimism about the company's potential to leverage its mRNA technology platform to address emerging infectious disease threats. The bird flu vaccine program underscores Moderna's commitment to advancing its pipeline and solidifying its position as a leading player in the global vaccine market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1189535129","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189535129","pubTimestamp":1737557202,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc.  shares surged 5.02% in intraday trading on Wednesday, January 22nd, fueled by news that the company secured a $590 million contract from the U.S. government to accelerate the development of a bird flu vaccine.The substantial contract award from the U.S. government is a significant boost for Moderna's efforts to expand its vaccine portfolio beyond its successful COVID-19 vaccine. The funds will be used to speed up the research, development, and clinical testing of a vaccine candida","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"美国政府授予5.9亿美元禽流感疫苗合同，Moderna股价飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) shares surged 5.02% in intraday trading on Wednesday, January 22nd, fueled by news that the company secured a $590 million contract from the U.S. government to accelerate the development of a bird flu vaccine.\nThe substantial contract award from the U.S. government is a significant boost for Moderna's efforts to expand its vaccine portfolio beyond its successful COVID-19 vaccine. The funds will be used to speed up the research, development, and clinical testing of a vaccine candidate targeting the highly pathogenic avian influenza virus, commonly known as bird flu.\nModerna's share price rally reflects investor optimism about the company's potential to leverage its mRNA technology platform to address emerging infectious disease threats. The bird flu vaccine program underscores Moderna's commitment to advancing its pipeline and solidifying its position as a leading player in the global vaccine market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}